GFA
NVO

Gallagher Fiduciary Advisors’s Novo Nordisk NVO Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,858
Closed -$221K – 302
2024
Q3 		$221K Sell
1,858
-20
-1% -$2.67K 0.04% 241
2024
Q2 		$268K Buy
1,878
+162
+9% +$21.5K 0.06% 174
2024
Q1 		$220K Buy
+1,716
New +$204K 0.01% 173

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Gallagher Fiduciary Advisors's NVO Position: Q4 2024 in Review

Gallagher Fiduciary Advisors sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 1,858 shares — an estimated $221K sold.

Gallagher Fiduciary Advisors first reported a position in NVO in Q1 2024 and held it in 3 quarters. The position peaked at $268K in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Gallagher Fiduciary Advisors reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Gallagher Fiduciary Advisors sold 1,858 Novo Nordisk shares in Q4 2024, an estimated $221K.
  • Gallagher Fiduciary Advisors first reported a position in Novo Nordisk in Q1 2024 and held it in 3 quarters.
  • Gallagher Fiduciary Advisors's Novo Nordisk position peaked at $268K in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Gallagher Fiduciary Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.